Adipharm Fine For Imitation To Act As Warning To Other Drugmakers

To read the full article, please choose one of the following options:

BMI View: While the value of the fine administered to Sofia-based drugmaker Adipharm for imitating one of Bayer's product is quite small, the decision by Bulgaria's Commission on the Protection of Competition (CPC) is an encouraging sign of the level of consumer and trademark protection in Bulgaria and should act as a warning to other companies in the region that may try and promote their own products by imitating more well-known brands. BMI notes that legislation relating to trademark protection and the regulation of advertising medicines in Bulgaria is now almost entirely harmonised with, or equivalent to, EU norms.